Cogent Biosciences Balance Sheet
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cogent Biosciences financial position
At the end of fiscal 2025, Cogent Biosciences reported total assets of $937.6 million, up 185.9% from a year earlier against total liabilities of $301.2 million. Shareholders' equity stood at $636.4 million, or 67.9% of assets. The company held $312.0 million in cash and equivalents against $222.9 million of debt, a net cash position of $89.1 million.
The current ratio (current assets divided by current liabilities) was 14.23, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.35.
Summary generated from market data by MetaCap's automated system. Methodology
Cogent Biosciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 312.01M | 98.17M | 53.23M | 139.89M | 219.68M | 242.19M | 37.42M | 55.67M | 28.27M |
| Short-Term Investments | 588.75M | 188.91M | 212.48M | 119.39M | 0 | — | — | 22.92M | 12.69M |
| Receivables | — | — | — | — | — | — | 2.00M | 1.67M | 830.00K |
| Total Current Assets | 910.36M | 296.47M | 270.77M | 264.97M | 222.63M | 244.91M | 40.59M | 81.00M | 42.38M |
| Property, Plant & Equipment | 5.46M | 6.47M | 8.34M | 7.78M | 1.71M | 134.00K | 1.86M | 3.25M | 4.11M |
| Long-Term Investments | — | — | 7.46M | 0 | — | — | — | — | — |
| Total Assets | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M | 250.92M | 49.42M | 85.93M | 49.12M |
| Accounts Payable | 9.50M | 12.01M | 10.65M | 5.84M | 3.48M | 732.00K | 3.18M | 1.52M | 1.35M |
| Total Current Liabilities | 63.95M | 55.71M | 38.17M | 26.85M | 17.08M | 13.09M | 13.25M | 24.95M | 11.19M |
| Long-Term Debt | 222.90M | 0 | — | — | — | — | — | — | — |
| Total Liabilities | 301.24M | 71.61M | 55.63M | 45.08M | 17.91M | 16.25M | 17.66M | 25.69M | 20.81M |
| Shareholders' Equity | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M | 234.67M | 31.76M | 60.23M | -48.85M |
| Retained Earnings | -1.19B | -859.48M | -603.62M | -411.21M | -270.97M | -198.70M | -123.89M | -92.06M | -51.34M |
| Total Debt | 222.90M | 0 | — | — | — | — | — | — | — |
| Net Cash (Debt) | 677.87M | 287.08M | 265.71M | 259.28M | 219.68M | 242.19M | 37.42M | 78.59M | 40.96M |
| Shares Outstanding | 160.98M | 110.46M | 86.12M | 69.89M | 43.81M | 32.35M | 7.67M | 30.06M | 10.20M |
This table shows 9 annual periods of Cogent Biosciences's balance sheet, from FY 2025 back to FY 2017, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow COGT's reporting calendar. What is a balance sheet?